Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon Alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients

Hepatology

Volumn 26, Issue 3, 1997, Pages 734-739

  Manesis, Emanuel K ^a   Papaioannou, Christos ^a   Gioustozi, Andreas ^a   Kafiri, Georgia ^a   Koskinas, John ^a   Hadziyannis, Stephanos J ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; DOSE RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030777190     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260327     Document Type: Article

References (40)

1. Davis GL, Lau JYN. Hepatitis C. In: Haubrich WS, Schaffner F, Berk JE, eds. Bockus Gastoenterology, 5th edition. Philadelphia, PA: Saunders, 1995:2082-2114.
2. Thomas HC. Chronic hepatitis C. Consultant Series (4) No 2: The Role of Interferons in Chronic Viral Hepatitis. Cheshire, UK: Gardiner-Caldwell Communications Ltd., 1994.
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
4. Viladomiou L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC, Esteban R, et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. HEPATOLOGY 1992;15:767-769.
5. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post transfusion hepatitis. HEPATOLOGY 1991;14:969-974.
6. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. HEPATOLOGY 1995;21:650-655.
7. Davies GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
8. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA. Interferon-β treatment in patients with chronic hepatitis C. A meta-analytic evaluation. Clin Drug Invest 1995;9:141-149.
9. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
10. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-17.
11. Davies GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
12. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. HEPATOLOGY 1994;19:820-828.
13. Jouet P, Roudot-Thoraval F, Dhumeau D, Metreau J-M, and Le Groupe Francais Pour L'Etude du Traitement des Hepatites Chroniques NANB/ C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994:106: 686-690.
14. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. HEPATOLOGY 1995;22: 700-706.
15. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1050-1056.
16. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, et al. Treatment of chronic hepatitis C with recombinant human interferon-α2α: results of a randomized controlled clinical trial. HEPATOLOGY 1994;19:1-5.
17. Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. HEPATOLOGY 1994;19:1342-1346.
18. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Yun Z-B, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. HEPATOLOGY 1995;21: 918-922.
19. Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatol 1995;23:497-502.
20. Knodell RG, Ishak HG, Blak WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
21. Romeo R, Thiers V, Driss F, Berthelot P, Nalpas B, Brecot C. Hepatitis C virus RNA in serum of blood donors with or without elevated transaminase levels. Transfusion 1993;33:529-533.
22. Davis G, Lau JY, Urdea MS, Neuwald PD, Wilbert JC, Lindsay K, Perrillo RP, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of the optimal conditions for specimen collection and in interferon-treated patients. HEPATOLOGY 1994;19:1321-1324.
23. Stuyver L Rossau R, Wyseur A, Duhamel M, Vanderborght B, van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:1093-1102.
24. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994;19(Suppl):1321-1324.
25. Shiffman ML, Hofmann CM, Luketic VAC, Sanyal AJ, Contos MJ, Mills AC. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. HEPATOLOGY 1996; 24:21-26.
26. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24: 778-789.
27. Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis, GV, Katsoulidou A, Retalis G, et al. Am J Gastroenterol 1996;91:1734-1738.
28. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis virus RNA as a predictor of a long-term response to interferon-α therapy. Ann Intern Med 1995;122:586-591.
29. Craxi A, Di Marco V, Almasio PL. Hepatic hepatitis virus RNA in chronic hepatitis C [Letter]. Ann Intern Med 1996;124:72.
30. Pol S, Jaffredo B, Nalpas B, Savada C, Berthelot P, Brechot C. Predictive value of HCV viremia after 3 months in the monitoring of antiviral therapy [Abstract]. HEPATOLOGY 1994;20:159A.
31. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15:82-91.
32. Fried MW. Therapy of chronic viral hepatitis. Med Clin North Am 1996;80:957-972.
33. Honda M, Kaneko S, Sakai A, Onoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. HEPATOLOGY 1994;20:1144-1151.
34. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. HEPATOLOGY 1994;20: 1121-1130.
35. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108:1104-1109.
36. Hino K, Sainokami S, Shimoda K, Iiono S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
37. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. HEPATOLOGY 1992;16:293-299.
38. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
39. Hadziyannis E, Weiner A, Papaioannou C, Psalidaki E, Kuo G, Chien D, Urdea M, et al. Antibodies to linear epitopes of HCV and HCV-RNA levels in chronic HCV infection [Abstract]. HEPATOLOGY 1992;16:107A.
40. Lau JY, Davis GL, Kniffen J, Quian KP, Urdea M, Chan C, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 1993;341:1501-1504.